5JNW

Crystal structure of bovine low molecular weight protein tyrosine phosphatase (LMPTP) mutant (W49Y N50E) complexed with vanadate and uncompetitive inhibitor


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.86 Å
  • R-Value Free: 0.209 
  • R-Value Work: 0.166 

wwPDB Validation 3D Report Full Report


This is version 1.3 of the entry. See complete history

Literature

Diabetes reversal by inhibition of the low-molecular-weight tyrosine phosphatase.

Stanford, S.M.Aleshin, A.E.Zhang, V.Ardecky, R.J.Hedrick, M.P.Zou, J.Ganji, S.R.Bliss, M.R.Yamamoto, F.Bobkov, A.A.Kiselar, J.Liu, Y.Cadwell, G.W.Khare, S.Yu, J.Barquilla, A.Chung, T.D.Y.Mustelin, T.Schenk, S.Bankston, L.A.Liddington, R.C.Pinkerton, A.B.Bottini, N.

(2017) Nat. Chem. Biol. 13: 624-632

  • DOI: 10.1038/nchembio.2344
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Obesity-associated insulin resistance plays a central role in type 2 diabetes. As such, tyrosine phosphatases that dephosphorylate the insulin receptor (IR) are potential therapeutic targets. The low-molecular-weight protein tyrosine phosphatase (LMP ...

    Obesity-associated insulin resistance plays a central role in type 2 diabetes. As such, tyrosine phosphatases that dephosphorylate the insulin receptor (IR) are potential therapeutic targets. The low-molecular-weight protein tyrosine phosphatase (LMPTP) is a proposed IR phosphatase, yet its role in insulin signaling in vivo has not been defined. Here we show that global and liver-specific LMPTP deletion protects mice from high-fat diet-induced diabetes without affecting body weight. To examine the role of the catalytic activity of LMPTP, we developed a small-molecule inhibitor with a novel uncompetitive mechanism, a unique binding site at the opening of the catalytic pocket, and an exquisite selectivity over other phosphatases. This inhibitor is orally bioavailable, and it increases liver IR phosphorylation in vivo and reverses high-fat diet-induced diabetes. Our findings suggest that LMPTP is a key promoter of insulin resistance and that LMPTP inhibitors would be beneficial for treating type 2 diabetes.


    Organizational Affiliation

    Department of Medicine, University of California, San Diego, La Jolla, California, USA.,Institute for Genetic Medicine, University of Southern California, Los Angeles, California, USA.,Center for Proteomics and Bioinformatics, Case Western Reserve University, Cleveland, Ohio, USA.,Division of Cellular Biology, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA.,Department of Orthopaedic Surgery and Department of Pediatrics, University of California, San Diego, La Jolla, California, USA.,Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA.,Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA.,Department of Respiratory, Inflammation and Autoimmunity, MedImmune LLC, Gaithersburg, Maryland, USA.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Low molecular weight phosphotyrosine protein phosphatase
A
159Bos taurusMutation(s): 0 
Gene Names: ACP1
EC: 3.1.3.48
Find proteins for P11064 (Bos taurus)
Go to Gene View: ACP1
Go to UniProtKB:  P11064
Small Molecules
Ligands 2 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
6LJ
Query on 6LJ

Download SDF File 
Download CCD File 
A
2-(4-{[3-(piperidin-1-yl)propyl]amino}quinolin-2-yl)benzonitrile
C24 H26 N4
PBIFICWHSUFSCR-UHFFFAOYSA-N
 Ligand Interaction
VO4
Query on VO4

Download SDF File 
Download CCD File 
A
VANADATE ION
O4 V
LSGOVYNHVSXFFJ-UHFFFAOYSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
6LJIC50: 460 nM BINDINGMOAD
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.86 Å
  • R-Value Free: 0.209 
  • R-Value Work: 0.166 
  • Space Group: C 2 2 21
Unit Cell:
Length (Å)Angle (°)
a = 60.347α = 90.00
b = 125.493β = 90.00
c = 45.251γ = 90.00
Software Package:
Software NamePurpose
REFMACrefinement
PDB_EXTRACTdata extraction
Aimlessdata scaling
PHASERphasing
XDSdata reduction

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
National Institutes of Health/National Institute of Diabetes and Digestive and Kidney DiseaseUnited StatesR01DK106233

Revision History 

  • Version 1.0: 2017-03-29
    Type: Initial release
  • Version 1.1: 2017-04-12
    Type: Database references
  • Version 1.2: 2017-05-24
    Type: Database references
  • Version 1.3: 2017-09-20
    Type: Author supporting evidence